- FDA approves Astellas drug for preventing kidney rejection
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Giant Eagle acquires Rx21 Specialty Pharmacy, enabling enhanced hepatitis C/organ transplant services
- CareMed selected to distribute Tarceva
NORTHBROOK, Ill. — Astellas Pharma has introduced a new drug for preventing the body from rejecting transplanted organs, the company said Thursday.
The drug maker announced the availability of Astagraf XL (tacrolimus) extended-release capsules in pharmacies. The drug is designed for use in kidney transplant patients with Genenetech's CellCept (mycophenolate mofetil) and corticosteroids, with or without induction of Novartis' Simulect (basiliximab).
"The availability of Astagraf XL marks a significant moment for the transplantation community, giving new adult kidney transplant recipients an additional option in their immunosuppressant care," Astellas Pharma US president James Robinson said. "Astellas has long been a leader in the field of transplant immunology, and we are proud to continue to advance care for transplant recipients."
Are you a nurse practitioner or physician's assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.